Tempest Therapeutics, Inc.
TPST
$6.71
$0.21573.32%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.18M | 2.99M | 3.75M | 3.63M | 3.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.92M | 10.55M | 9.58M | 7.97M | 7.51M |
| Operating Income | -13.92M | -10.55M | -9.58M | -7.97M | -7.51M |
| Income Before Tax | -13.81M | -10.56M | -9.57M | -7.90M | -7.49M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.81M | -10.56M | -9.57M | -7.90M | -7.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.81M | -10.56M | -9.57M | -7.90M | -7.49M |
| EBIT | -13.92M | -10.55M | -9.58M | -7.97M | -7.51M |
| EBITDA | -13.87M | -10.45M | -9.43M | -7.89M | -7.43M |
| EPS Basic | -4.38 | -5.32 | -5.52 | -4.62 | -5.00 |
| Normalized Basic EPS | -2.74 | -3.32 | -3.45 | -2.89 | -3.12 |
| EPS Diluted | -4.38 | -5.32 | -5.52 | -4.62 | -5.00 |
| Normalized Diluted EPS | -2.74 | -3.32 | -3.45 | -2.89 | -3.12 |
| Average Basic Shares Outstanding | 3.15M | 1.99M | 1.73M | 1.71M | 1.50M |
| Average Diluted Shares Outstanding | 3.15M | 1.99M | 1.73M | 1.71M | 1.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |